The Poliovirus Receptor pipeline drugs market research report outlays comprehensive information on the Poliovirus Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Poliovirus Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Unspecified Cancer, and Solid Tumor. It also reviews key players involved in Poliovirus Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Poliovirus Receptor pipeline targets constitutes close to seven molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 4, and 1 respectively.
Poliovirus Receptor overview
The Poliovirus Receptor referred to as PVR or CD155, is a protein that in humans is encoded by a gene PVR. It belongs to immunoglobulin superfamily and serves as the cellular receptor for the poliovirus. This receptor is essential for the virus to enter and infect host cells. This receptor play a role in axonal transport of poliovirus, by targeting virion-PVR-containing endocytic vesicles to the microtubular network through interaction with DYNLT1. This interaction would drive the virus-containing vesicle to the axonal retrograde transport. The poliovirus is the causative agent of poliomyelitis, a viral infection that can lead to paralysis. The virus primarily targets and infects the gastrointestinal tract, but it can spread to the nervous system, causing damage to motor neurons. PVR/CD155 is expressed on the surface of certain cells, and the poliovirus binds to this receptor as a crucial step in the process of entering and infecting the host cell. Understanding the interaction between the virus and its receptor is important for developing strategies to prevent or treat poliovirus infections.
For a complete picture of Poliovirus Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
